From GlobeNewswire: 2024-07-26 07:00:00

Chemomab Therapeutics Ltd. announced it has regained compliance with the minimum bid price requirement set forth by Nasdaq after its ADSs closed at $1.00 or more for 10 consecutive business days. The company previously faced non-compliance due to the closing price of its ADSs falling below $1.00 for 30 consecutive days. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with positive results from trials for CM-101. The company’s CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.



Read more at GlobeNewswire: Chemomab Therapeutics Regains Compliance With Nasdaq